Gilead Sciences Inc has seen record-breaking sales of its new Hepatitis C drug, Sovaldi, with over $2 Billion in the first quarter- the highest EVER for a new medicine. Read more here. (Source: Deena Beasley, Reuters, 4/22/14).
Gilead Sciences Inc has seen record-breaking sales of its new Hepatitis C drug, Sovaldi, with over $2 Billion in the first quarter- the highest EVER for a new medicine. Read more here. (Source: Deena Beasley, Reuters, 4/22/14).